157 lines
50 KiB
Text
157 lines
50 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK23014">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK23014/?report=reader">
|
|
<meta name="ncbi_pagename" content="Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-111In - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-111In - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/MLS128-SA-biotin/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/CNT-rituximab111In/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-111In">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2007/12/12">
|
|
<meta name="citation_author" content="Arvind Chopra">
|
|
<meta name="citation_pmid" content="20641221">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK23014/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-111In">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Arvind Chopra">
|
|
<meta name="DC.Date" content="2007/12/12">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK23014/">
|
|
<meta name="description" content="The epidermal growth factor (EGF) and its receptor (EGFR) are known to play a role in the neoplastic transformation of cells (1). The EGFR is a tyrosine kinase receptor family that includes four members, EGFR and three other human EGF receptors (HERs) designated as HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4. The four receptors constitute the HER-kinase axis and regulate cellular responses through complex receptor–ligand interactions. The various signal transduction pathways that respond to EGFR activation and mediate cell responses have been described by Brandt et al. (2). The various EGFRs are known to be amplified, mutated, or overexpressed in several cancers and are a target for the development of pharmaceutical agents that inhibit either the receptor or the signal transduction pathway (3). It has also been reported that the detection of circulating ErbB2-positive tumor cells indicates a poor prognosis for the cancer patient (4). A variety of inhibitors, including small molecules, antibodies, vaccines, and gene therapies, have been developed and tested against the EGFRs for the treatment of cancer (5, 6). However, to achieve therapeutic effects the receptor or signal transduction pathway must be involved in maintenance of the malignant phenotype because HER inhibitor therapy does not necessarily result in treatment of a cancer (7).">
|
|
<meta name="og:title" content="Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-111In">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="The epidermal growth factor (EGF) and its receptor (EGFR) are known to play a role in the neoplastic transformation of cells (1). The EGFR is a tyrosine kinase receptor family that includes four members, EGFR and three other human EGF receptors (HERs) designated as HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4. The four receptors constitute the HER-kinase axis and regulate cellular responses through complex receptor–ligand interactions. The various signal transduction pathways that respond to EGFR activation and mediate cell responses have been described by Brandt et al. (2). The various EGFRs are known to be amplified, mutated, or overexpressed in several cancers and are a target for the development of pharmaceutical agents that inhibit either the receptor or the signal transduction pathway (3). It has also been reported that the detection of circulating ErbB2-positive tumor cells indicates a poor prognosis for the cancer patient (4). A variety of inhibitors, including small molecules, antibodies, vaccines, and gene therapies, have been developed and tested against the EGFRs for the treatment of cancer (5, 6). However, to achieve therapeutic effects the receptor or signal transduction pathway must be involved in maintenance of the malignant phenotype because HER inhibitor therapy does not necessarily result in treatment of a cancer (7).">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK23014/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/KCCYSLDOTA111In/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK23014/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D160C7D63F7E10000000000C100A9.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK23014/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/MLS128-SA-biotin/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-111In</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/CNT-rituximab111In/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK23014/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK23014/&text=Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1%2C4%2C7%2C10-tetraazacyclododecane-N%2CN'%2CN''%2CN'''-tetraacetic%20acid-111In"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK23014/?report=classic">Switch to classic view</a><a href="/books/NBK23014/pdf/Bookshelf_NBK23014.pdf">PDF (140K)</a><a href="/books/NBK23014/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK23014%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D160C7D63F7E10000000000C100A9.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK23014_"><span class="title" itemprop="name">Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-<i>N,N',N'',N'''</i>-tetraacetic acid-<sup>111</sup>In</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm"><sup>111</sup>In-DOTA-(GSG)-KCCYSL</div><p class="contribs">Chopra A.</p><p class="fm-aai"><a href="#_NBK23014_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figKCCYSLDOTA111InT1"><a href="/books/NBK23014/table/KCCYSLDOTA111In.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figKCCYSLDOTA111InT1" rid-ob="figobKCCYSLDOTA111InT1"><img class="small-thumb" src="/books/NBK23014/table/KCCYSLDOTA111In.T1/?report=thumb" src-large="/books/NBK23014/table/KCCYSLDOTA111In.T1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="KCCYSLDOTA111In.T1"><a href="/books/NBK23014/table/KCCYSLDOTA111In.T1/?report=objectonly" target="object" rid-ob="figobKCCYSLDOTA111InT1">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Rodents
|
|
</p></div></div><div id="KCCYSLDOTA111In.Background"><h2 id="_KCCYSLDOTA111In_Background_">Background</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=ErbB2+binding+radiolabeled+peptide+" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>The epidermal growth factor (EGF) and its receptor (EGFR) are known to play a role in the neoplastic transformation of cells (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.1" rid="KCCYSLDOTA111In.EXTYLES.1">1</a>). The EGFR is a tyrosine kinase receptor family that includes four members, EGFR and three other human EGF receptors (HERs) designated as HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4. The four receptors constitute the HER-kinase axis and regulate cellular responses through complex receptor–ligand interactions. The various signal transduction pathways that respond to EGFR activation and mediate cell responses have been described by Brandt et al. (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.2" rid="KCCYSLDOTA111In.EXTYLES.2">2</a>). The various EGFRs are known to be amplified, mutated, or overexpressed in several cancers and are a target for the development of pharmaceutical agents that inhibit either the receptor or the signal transduction pathway (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.3" rid="KCCYSLDOTA111In.EXTYLES.3">3</a>). It has also been reported that the detection of circulating ErbB2-positive tumor cells indicates a poor prognosis for the cancer patient (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.4" rid="KCCYSLDOTA111In.EXTYLES.4">4</a>). A variety of inhibitors, including small molecules, antibodies, vaccines, and gene therapies, have been developed and tested against the EGFRs for the treatment of cancer (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.5" rid="KCCYSLDOTA111In.EXTYLES.5">5</a>, <a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.6" rid="KCCYSLDOTA111In.EXTYLES.6">6</a>). However, to achieve therapeutic effects the receptor or signal transduction pathway must be involved in maintenance of the malignant phenotype because HER inhibitor therapy does not necessarily result in treatment of a cancer (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.7" rid="KCCYSLDOTA111In.EXTYLES.7">7</a>).</p><p>The use of antibodies alone against EGFR (e.g., cetuximab) and ErbB2 (e.g., trastuzumab) for the treatment of cancer has yielded only moderate results, and it has been observed that antibodies are most useful when used in combination with chemotherapy (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.8" rid="KCCYSLDOTA111In.EXTYLES.8">8</a>). In some cases cardiotoxicity has been reported in individuals treated with trastuzumab in combination with some chemotherapeutic agents (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.9" rid="KCCYSLDOTA111In.EXTYLES.9">9</a>). In an effort to develop better and safer anti-cancer drugs, investigators have attempted to use peptides that bind to receptors on tumors to treat the disease (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.10" rid="KCCYSLDOTA111In.EXTYLES.10">10</a>, <a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.11" rid="KCCYSLDOTA111In.EXTYLES.11">11</a>). The development of peptide pharmaceuticals has also been pursued because, compared to the larger biomolecules such as antibodies, these molecules are easier to synthesize and have low immunogenicity, rapid blood clearance, and a higher uptake in tumor tissue (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.12" rid="KCCYSLDOTA111In.EXTYLES.12">12</a>). Using bacteriophage technology, a peptide of six amino acids, lys-cys-cys-tyr-ser-leu (KCCYSL), that specifically recognizes and binds the extracellular domain of ErbB2 was identified, and the investigators hypothesized that the peptide could be developed into an imaging and therapeutic agent against cancer cells that overexpress ErbB2 (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.13" rid="KCCYSLDOTA111In.EXTYLES.13">13</a>). As an extension to the earlier study, the tumor imaging and targeting ability of KCCYSL was evaluated after labeling with radioactive indium (<sup>111</sup>In). Using the labeled peptide, Kumar et al. performed <i>in vitro</i> and <i>in vivo</i> studies in human breast carcinoma cells that overexpress ErbB2 and in xenografted mice (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>).</p></div><div id="KCCYSLDOTA111In.Synthesis"><h2 id="_KCCYSLDOTA111In_Synthesis_">Synthesis</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=ErbB2+binding+radiolabeled+peptide+synthesis" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>The procedure used to identify and characterize KCCYSL from a phage display library as an ErbB2 extracellular domain binding peptide was described in detail by Karasseva et al. (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.13" rid="KCCYSLDOTA111In.EXTYLES.13">13</a>). The synthesis of <sup>111</sup>In-labeled KCCYSL was described by Kumar et al. (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). The peptide was synthesized using solid-phase Fmoc technology on a peptide synthesizer. The bifunctional chelator 1,4,7,10-tetraazacyclododecane-<i>N,N',N'',N'''</i>-tetraacetic acid (DOTA) was linked with KCCYSL through a gly-ser-gly (GSG) spacer placed between the amino terminus of DOTA and the hexapeptide to obtain DOTA-(GSG)-KCCYSL. For use as control, a scrambled peptide version (KYLCSC) was also prepared similarly. The peptides were purified by reverse-phase high-pressure liquid chromatography (RP-HPLC) on a Vydac C<sub>18</sub> column. The peptides were freeze-dried and stored at -20°C until required. Electrospray ionization-mass spectrometery was used to confirm the identity of the peptides. Details of how this technique was used to confirm the identity of the peptides were not provided in the publication.</p><p>For radiolabeling, the respective peptides were mixed with radioactive [<sup>111</sup>In]indium chloride in ammonium acetate buffer (pH 5.5) (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). The mixture was incubated at 85°C for 60 min, and the reaction was terminated by the addition of ethylenediamine tetraacetic acid to remove unreacted <sup>111</sup>In. The labeled conjugates were then purified by RP-HPLC and flush-dried with nitrogen gas, and the pH was adjusted to 8.0 with sodium phosphate buffer in saline. Tris(2-carboxyethyl)phosphine hydrochloride was then added to the peptide stock solution to prevent oxidation of the cysteine thiols. Although the radiolabeling efficiency of the reaction was reported to be 40–50%, the specific activity, radiochemical yield, and purity of the product was not provided by the investigators (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). The labeled peptide was reported to be stable for 12 h in phosphate-buffered saline and for at least 1 h in mouse serum.</p></div><div id="KCCYSLDOTA111In.In_Vitro_Studies_Tes"><h2 id="_KCCYSLDOTA111In_In_Vitro_Studies_Tes_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=ErbB2+binding+radiolabeled+peptide+in+vitro" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>The <i>in vitro</i> binding of <sup>111</sup>In-DOTA(GSG)-KCCYSL was investigated in <a href="http://www.atcc.org/common/catalog/numSearch/numResults.cfm?atccNum=HTB-129" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MDA-MB-435</a> cells that express ErbB2 receptors (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). For the same study, <a href="http://www.atcc.org/common/catalog/numSearch/numResults.cfm?atccNum=CCL-243" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">K-562</a> cells, which do not express ErbB2 receptors, were used as negative controls. The cells were incubated with the radiolabeled peptide for various times at 37°C, and binding of the label with MDA-MB-435 cells increased gradually and reached saturation by 2 h. Under the same conditions the K-562 cells bound little radioactivity. Neither cell line bound the scrambled version of the labeled peptide. In competition experiments with MDA-MB-435 cells, using an increasing concentration of cold DOTA(GSG)-KCCYSL, the binding of radioactivity decreased in a concentration-dependent manner, indicating a specificity of the labeled peptide for ErbB2 receptors (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). The 50% inhibitory concentration of the labeled peptide with these cells was determined to be 42.5 ± 2.67 nM.</p><p>To determine internalization of bound radioactivity, the MDA-MB-435 cells were incubated with the labeled peptide for different time periods and washed with ice-cold cell-binding medium to remove any unbound radioactivity. The cells were then incubated on ice with acetic acid in saline for 5 min and pelleted by centrifugation. Radioactivity was counted to determine the internalized (cell pellet) and the surface bound fraction (supernatant). The cell surface–associated label increased up to 2 h and ~11% of the total radioactivity was determined to be internalized during this period (<i>P</i> < 0.0001).</p></div><div id="KCCYSLDOTA111In.Animal_Studies"><h2 id="_KCCYSLDOTA111In_Animal_Studies_">Animal Studies</h2><div id="KCCYSLDOTA111In.Rodents"><h3>Rodents</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=ErbB2+binding+radiolabeled+peptide+rodentia" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>The biodistribution of <sup>111</sup>In-DOTA(GSG)-KCCYSL was investigated in severe combined immunodeficient mice that had MDA-MB-435 cells implanted in the shoulder (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). The radioactive peptide was injected into the mice through the tail vein, and the animals were euthanized in groups of three at different time points. The tissues of interest were collected and counted for incorporated radioactivity, and the uptake was expressed as a percentage of the injected radioactivity dose per gram (% ID/g). Distribution of the radiolabeled peptide was determined at various time points between 15 min and 24 h after administration (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). The tumor uptake of radioactivity decreased from 2.12 ± 0.32% ID/g at 30 min to 0.66 ± 0.11% ID/g at 2 h and to 0.33 ± 0.05% ID/g at 4 h. The blood radioactivity level was 3.16 ± 0.33% ID/g at 15 min after the injection and dropped to 0.13 ± 0.03% ID/g at 2 h. This indicated a rapid uptake of radioactivity by the tumor and a clearance from the blood during the same period. The tumor/blood ratio was 5.0 at the end of 2 h. A radioactivity peak of 10.51 ± 0.07% ID/g was observed in the kidneys at 15 min, and this subsequently decreased to 5–7% ID/g for the next 3 h after injection. This was probably because the radioactive peptide and its breakdown products were excreted primarily through the urinary route. A high level of radioactivity (3.18 ± 0.16% ID/g) was also detected in the lungs at 15 min after the injection, but this level decreased to 0.23 ± 0.17% ID/g at 4 h. The investigators suggested that the lungs showed a high amount of radioactivity probably because these organs are highly vascularized and have a high blood perfusion rate. During the same period, little radioactivity was observed in the other vital organs, muscle, or bone (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>).</p><p>The specificity of tumor radioactivity uptake was evaluated by performing a competition experiment using unlabeled In-DOTA(GSG)-KCCYSL (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). The mice (<i>n</i> = 3) were injected with the unlabeled peptide (~0.07 μM) through the tail vein followed by administration of the labeled homolog 15 min later. The labeled peptide alone was administered to another group of mice (<i>n</i> = 3) to serve as the positive control. Results indicated that uptake of the radioactive peptide was blocked by 50% in tumors of mice injected with the non-radioactive peptide (<i>P</i> = 0.0012). Administration of the non-labeled peptide did not affect the percentage of radioactivity uptake per gram of tissue in the normal organs, including the kidneys and the lungs, of these animals (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). The investigators suggested that these observations indicate that uptake of the radiolabeled peptide by the tumor was receptor-mediated, but the label observed in the kidneys and the lungs was the result of non-specific uptake of the peptide (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>).</p><p><i>In vivo</i> single-photon emission computed tomography of mice injected with <sup>111</sup>In-DOTA(GSG)-KCCYSL showed that the radioactivity accumulated mainly in the xenografted human breast carcinoma cell tumors and the kidneys (<a class="bibr" href="#KCCYSLDOTA111In.EXTYLES.14" rid="KCCYSLDOTA111In.EXTYLES.14">14</a>). Very low radioactivity was detected in the hepatobiliary or other systems of the animals. From these results the investigators concluded that <sup>111</sup>In-DOTA(GSG)-KCCYSL was a promising peptide for the imaging of ErbB2-positive tumors.</p></div><div id="KCCYSLDOTA111In.Other_NonPrimate_Mam"><h3>Other Non-Primate Mammals</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=ErbB2+binding+radiolabeled+peptide+Non+primate+Mammals" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div><div id="KCCYSLDOTA111In.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=ErbB2+binding+radiolabeled+peptide+Non+Human+Primates" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div></div><div id="KCCYSLDOTA111In.Human_Studies"><h2 id="_KCCYSLDOTA111In_Human_Studies_">Human Studies</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=ErbB2+binding+radiolabeled+peptide+Humans" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div><div id="KCCYSLDOTA111In.NIH_Support"><h2 id="_KCCYSLDOTA111In_NIH_Support_">NIH Support</h2><p>The imaging study reported in this chapter was funded by an NIH P50 Grant #CA103130.</p></div><div id="KCCYSLDOTA111In.references"><h2 id="_KCCYSLDOTA111In_references_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.1">Gross M.E. , Shazer R.L. , Agus D.B. <span class="ref-title">Targeting the HER-kinase axis in cancer </span><span class="ref-journal">Semin Oncol</span> 2004<strong>31</strong>Suppl 31:9–20. [<a href="https://pubmed.ncbi.nlm.nih.gov/15052539" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15052539</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.2">Brandt B. , Meyer-Staeckling S. , Schmidt H. , Agelopoulos K. , Buerger H. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. <span><span class="ref-journal">Clin Cancer Res. </span>2006;<span class="ref-vol">
|
|
<strong>12</strong>
|
|
</span>(24):7252–60.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17189396" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17189396</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.3">Smith-Jones P.M. , Solit D.B. , Akhurst T. , Afroze F. , Rosen N. , Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. <span><span class="ref-journal">Nat Biotechnol. </span>2004;<span class="ref-vol">
|
|
<strong>22</strong>
|
|
</span>(6):701–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15133471" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15133471</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.4">Wulfing P. , Borchard J. , Buerger H. , Heidl S. , Zanker K.S. , Kiesel L. , Brandt B. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. <span><span class="ref-journal">Clin Cancer Res. </span>2006;<span class="ref-vol">
|
|
<strong>12</strong>
|
|
</span>(6):1715–20.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16551854" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16551854</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.5">Dancey J.E. Recent advances of molecular targeted agents: opportunities for imaging. <span><span class="ref-journal">Cancer Biol Ther. </span>2003;<span class="ref-vol">
|
|
<strong>2</strong>
|
|
</span>(6):601–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14688462" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14688462</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.6">Hudis C.A. Trastuzumab--mechanism of action and use in clinical practice. <span><span class="ref-journal">N Engl J Med. </span>2007;<span class="ref-vol">
|
|
<strong>357</strong>
|
|
</span>(1):39–51.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17611206" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17611206</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.7">Bates S.E. , Fojo T. Epidermal growth factor receptor inhibitors: a moving target? <span><span class="ref-journal">Clin Cancer Res. </span>2005;<span class="ref-vol">
|
|
<strong>11</strong>
|
|
</span>(20):7203–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16243788" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16243788</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.8">Khalil M.Y. , Grandis J.R. , Shin D.M. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. <span><span class="ref-journal">Expert Rev Anticancer Ther. </span>2003;<span class="ref-vol">
|
|
<strong>3</strong>
|
|
</span>(3):367–80.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12820779" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12820779</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.9">Seidman A. , Hudis C. , Pierri M.K. , Shak S. , Paton V. , Ashby M. , Murphy M. , Stewart S.J. , Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. <span><span class="ref-journal">J Clin Oncol. </span>2002;<span class="ref-vol">
|
|
<strong>20</strong>
|
|
</span>(5):1215–21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11870163" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11870163</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.10">Abraham J.M. , Sato F. , Cheng Y. , Paun B. , Kan T. , Olaru A. , Jin Z. , Yang J. , Agarwal R. , David S. , Hamilton J.P. , Ito T. , Mori Y. , Meltzer S.J. Novel Decapeptides that Bind Avidly and Deliver Radioisotope to Colon Cancer Cells. <span><span class="ref-journal">PLoS ONE. </span>2007;<span class="ref-vol">
|
|
<strong>2</strong>
|
|
</span>(10):e964.</span> [<a href="/pmc/articles/PMC1978517/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1978517</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17912343" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17912343</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.11">Nava-Parada P. , Emens L.A. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. <span><span class="ref-journal">Curr Opin Mol Ther. </span>2007;<span class="ref-vol">
|
|
<strong>9</strong>
|
|
</span>(5):490–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17932813" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17932813</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.12">Landon L.A. , Zou J. , Deutscher S.L. Is phage display technology on target for developing peptide-based cancer drugs? <span><span class="ref-journal">Curr Drug Discov Technol. </span>2004;<span class="ref-vol">
|
|
<strong>1</strong>
|
|
</span>(2):113–32.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16472251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16472251</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.13">Karasseva N.G. , Glinsky V.V. , Chen N.X. , Komatireddy R. , Quinn T.P. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. <span><span class="ref-journal">J Protein Chem. </span>2002;<span class="ref-vol">
|
|
<strong>21</strong>
|
|
</span>(4):287–96.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12168699" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12168699</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="KCCYSLDOTA111In.EXTYLES.14">Kumar S.R. , Quinn T.P. , Deutscher S.L. Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor Expressing Breast Carcinomas. <span><span class="ref-journal">Clin Cancer Res. </span>2007;<span class="ref-vol">
|
|
<strong>13</strong>
|
|
</span>(20):6070–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17947470" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17947470</span></a>]</div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK23014_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Arvind Chopra</span>, PhD<div class="affiliation small">
|
|
National Center for Biotechnology Information, NLM, NIH, Bethesda, MD 20894,
|
|
<span class="before-email-separator"></span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.mln.ibcn@dacim" class="oemail">vog.hin.mln.ibcn@dacim</a>
|
|
</div></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">November 8, 2007</span>; Last Update: <span itemprop="dateModified">December 12, 2007</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Chopra A. Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-111In. 2007 Nov 8 [Updated 2007 Dec 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/MLS128-SA-biotin/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/CNT-rituximab111In/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobKCCYSLDOTA111InT1"><div id="KCCYSLDOTA111In.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK23014/table/KCCYSLDOTA111In.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__KCCYSLDOTA111In.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-<i>N</i>,<i>N</i>',<i>N</i>'',<i>N</i>'''-tetraacetic acid-<sup>111</sup>In</td><td rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>111</sup>In-DOTA-(GSG)-KCCYSL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Peptide</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ErbB-2 extracellular domain</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Receptor-ligand binding</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Single-photon emission computed tomography (SPECT) or planar gamma imaging</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>111</sup>In</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li></ul>
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Rodents
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|